Ultrahigh-throughput Identification of Molecular Targets of Natural Products

天然产物分子靶标的超高通量鉴定

基本信息

批准号：
9263893
负责人：
DAOJING WANG
金额：
$ 81.13万
依托单位：
NEWOMICS, INC
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-06-01 至 2019-09-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9263893
关键词：
Binding Bioinformatics Biological Biological Assay Biological Availability Biomedical Research Blood Blood Cells Blood specimen Businesses Cell Line Clinical Research Collaborations Communities Coupled Crude Extracts Databases Development Diabetes Mellitus Diabetic mouse Diagnosis Disease Progression Drug Kinetics Foundations Human KRAS2 gene Laboratories Libraries Liquid Chromatography Malignant Neoplasms Mass Spectrum Analysis Microfluidic Microchips Mississippi Molecular Target Monitor Natural Products Pathway interactions Performance Pharmaceutical Preparations Phase Plants Preparation Proteins Proteome Proteomics Publishing Reporting Resveratrol Sampling Sensitivity and Specificity Serum Albumin Silicon Small Business Innovation Research Grant Source Spectrometry, Mass, Electrospray Ionization Technology Therapeutic Effect Tissues Toxic effect Universities Validation Vendor Walkers analog base commercialization drug development drug discovery high throughput screening in vivo industry partner innovation insight mass spectrometer metabolome metabolomics mouse model next generation novel therapeutics operation public health relevance research and development response screening therapeutic evaluation treatment response

项目摘要

DESCRIPTION (provided by applicant): Natural products are rich sources for potential drugs. To accelerate drug discovery from natural products, it is imperative to identify their molecular targets, and mechanistically elucidate their bioavailability, toxicity, and therapeutic effects. However, there remain several challenges in the field. Among them, there is currently no technical platform that could perform mechanistic studies from the "hits" to "leads" using the small volumes of samples that are typically encountered in quantitative high-throughput screening or obtained from biological and clinical studies. To tackle these challenges and in response to RFA-AT-16-003, Newomics Inc. proposes to complete development of its product, a multiomics platform for high-throughput and high-content bioassays of natural products. The Phase II project is built upon the promising results generated from our Phase I project. In Phase I, we have developed ESI-MS assays to screen the interactions between molecular targets and natural products from libraries with different complexity. In Phase II, we will complete development of multiomics assays for commercialization, through working closely with industry partners, academic collaborators, and business consultants. Once developed, Newomics' Omics-chip may become a universal platform for high-throughput identification of molecular targets of natural products in the blood or other tissues, and lay a new foundation for drug discovery and development.

描述（由申请人提供）：天然产物是潜在药物的丰富来源，为了加速天然产物的药物发现，必须确定其分子靶点，并从机制上阐明其生物利用度、毒性和治疗作用。然而，仍然存在一些问题。其中，目前还没有技术平台可以使用定量高通量筛选中通常遇到的或从其中获得的少量样品来进行从“命中”到“先导”的机制研究。为了应对这些挑战并响应 RFA-AT-16-003，Newomics Inc. 提议完成其产品的开发，即用于天然产物高通量和高含量生物测定的多组学平台。 II 项目建立在我们第一阶段项目产生的有希望的结果的基础上，在第一阶段，我们开发了 ESI-MS 检测方法，以筛选不同复杂性的分子靶标和天然产物之间的相互作用。在第二阶段，我们将完成开发。的通过与行业合作伙伴、学术合作者和商业顾问的密切合作，Newomics 的 Omics 芯片一旦开发出来，可能会成为高通量鉴定血液或其他组织中天然产物分子靶点的通用平台。为药物发现和开发奠定新的基础。